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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A192percentage methylation of the CpG site located at 116-bp in 5-aza-dC
culture was lower than that in control culture. In vitro DNAmethylation
was noted to decrease IL8 promoter basal activity. Furthermore, NF-kB,
AP-1 and C/EBP strongly enhanced IL8 promoter activity whilst DNA
methylation inhibited the effects of these three transcription factors.
Finally, point mutations created on any single CpG site or two CpG sites
resulted in a signiﬁcant increase in IL8 promoter activity by 3.4 to 5.4
fold.
Conclusions: The current study demonstrates that the increased
expression of IL8 in human osteoarthritic chondrocytes is regulated by
DNA demethylation in cooperation with transcription factors. We show
for the ﬁrst time that the percentage methylation of speciﬁc CpG sites
correlates with IL8 gene expression level in clinical OA samples. Fur-
thermore, DNA methylation of speciﬁc CpG sites appears to be a basal
repressionmechanism of IL8 expression. These ﬁndings offer a potential
predictive marker and a putative target, in this inﬂammatory chemo-
kine, for pharmacological intervention in the treatment of OA and,
potentially, other arthritic diseases.
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Purpose: Runt-related transcription factor 2 (RUNX2) also known as
core-binding factor subunit alpha-1 belongs to the family of runt
domain transcription factors. RUNX2 is essential for the maturation of
osteoblasts and both intramembranous and endochondral ossiﬁcation.
In the articular cartilage, RUNX2 regulates MMP13 expression and is
involved in the pathophysiology of osteoarthritis (OA). However, tran-
scriptional regulation mechanism of RUNX2 in articular chondrocytes is
far from clear. RUNX2 has two major isoforms. Type II isoform is
restricted to osseous cells and mature chondrocytes, and the tran-
scription is initiated at the distal promoter P1. Importantly the RUNX2
P1 promoter has a fragment containing a 600bp of sequence upstream
of the transcription start sufﬁcient for promoter activity, with only a few
CpG sites contained in this region. We hypothesized that methylation
status at speciﬁc CpG sites in the RUNX2 P1 promoter predominantly
regulate promoter activity and correlate with messenger RNA levels in
human chondrocytes.
Methods: The superﬁcial and deep zone of cartilage from patients with
a fracture of the neck of femur (NOF; n ¼ 11) were used for isolation of
non-OA/healthy chondrocytes, whereas cartilage pieces adjacent to
weight-bearing areas of OA femoral heads (lacking surface zones) were
harvested to obtain OA chondrocytes (n ¼ 15). Gene expression levels
and percentage methylation of CpG sites within the RUNX2 P1 pro-
moter were quantiﬁed by qRT-PCR and bisulﬁte pyrosequencing. Iso-
lated primary human chondrocyte samples (n ¼ 6) were cultured for 5
weeks in 3 groups: (i) cultured without treatment (control culture) and
(ii) cultured using 2 mM 5-azadeoxycytidine (5-aza-dC). The effect of
CpG methylation on RUNX2 promoter activity was determined using a
CpG-free vector. Furthermore, to determine the CpG sites critical for
RUNX2 promoter activity, RUNX2 wild type promoter construct activity
was compared against 4 vectors containing mutations at different CpG
sites.
Results: RUNX2 expression in OA and NOF deep chondrocytes were 34-
fold (p < 0.01) and 79-fold (p < 0.01) higher compared to NOF super-
ﬁcial chondrocytes. OA chondrocytes displayed a 10%, 14%, 32% and 41%
statistically signiﬁcant (P<0.01) reduction in methylation status at the
720, 686, 336 and þ17 CpG sites respectively, whereas NOF deep
chondrocytes a 13% and 19% reduction at the -336 and þ17 CpG sites. A
signiﬁcant negative correlation was observed between RUNX2 gene
expression and the percentage methylation of the CpG sites in OA
chondrocytes. MMP13 expression in OA chondrocytes was 27-fold and
89-fold higher than observed n NOF superﬁcial and deep chondrocytes,
respectively. A signiﬁcant positive correlation was observed between
RUNX2 and MMP13 gene expressions in OA chondrocytes. RUNX2
expression by chondrocytes cultured using 5-aza-dCwas observed to be
3.3-fold higher than in control culture chondrocytes. Signiﬁcantly, the
percentage methylation of the CpG site located at 336-bp in 5-aza-dC
culture was lower than observed in control culture (55% vs. 87%). In
vitro DNA methylationwas noted to decrease RUNX2 promoter activity.Point mutations (CG to TG) created at the 336 and þ17 CpG sites
resulted in a signiﬁcant reduction in RUNX2 P1 promoter activity.
Conclusions: The current studies show that the increased expression of
MMP13 in human osteoarthritic chondrocytes is correlated with RUNX2
expression. Critically, we show, methylation status of speciﬁc CpG sites
in the P1 promoter is a key regulator of RUNX2 expression in human
chondrocytes. These studies show for the ﬁrst time that the percentage
methylation of speciﬁc CpG sites correlates with RUNX2 gene expres-
sion level in clinical OA samples. Furthermore, point mutations created
at the 336 and þ17 CpG sites resulted in a signiﬁcant reduction in
RUNX2 P1 promoter activity. These ﬁndings indicate that CpG sites
located at 336 and þ17 are crucial regulators of RUNX2 transcription
and offer a putative target for pharmacological intervention in the
treatment of OA.
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Purpose: Signiﬁcant inﬂuence of the mtDNA haplogroups on radio-
graphic progression of knee OA (KOA) has been reported. For the
present study, we investigated the inﬂuence of the mtDNA hap-
logroups on radiographic KOA progression in subjects of the CHECK
(Cohort Hip and Cohort Knee) cohort, a running 10-year prospective
multi-center cohort of subjects, with pain and/or stiffness of one and/
or both knees
Methods: We assigned the mtDNA haplogroups to the entire CHECK
cohort (n¼1002 subjects). For this work, according to the criteria
reported elsewhere (van Spil et al. Osteoarthritis Cartilage
2012;20:1278-85), we have selected subjects that did show radio-
graphic KOA at baseline (K&L grade¼1 for the left and/or right knee
since maximum baseline K&L grade¼1, in accordance with the early-
stage OA in CHECK subjects), reaching a total of n¼417 subjects. Pro-
gression in these subjects was deﬁned as an increase of 1 K&L grade
for the left and/or right knee during 5 years follow-up period.
Appropriate statistical analyses, including chi-square contingency
tables, logistic regression models adjusting by gender, age, body mass
index (BMI), bilateral KOA and total WOMAC at baseline, as well as
Receiver Operating Curve (ROC) with their respective Area Under the
Curve (AUC), were carried out using SPSS software (v.19)
Results: The 417 subjects that met the eligibility criteria to study
radiographic progression included 81.1% females and 18.9%males, they
were older than 45 years (mean age: 56.24±5.07 years; range: 45-66)
and had a mean BMI of 26.80 Kg/m2 (range: 15.43-48.85). Chi-square
analysis revealed that the mtDNA haplogroup T signiﬁcantly asso-
ciated with lower risk of radiographic progression (OR¼0.467;
CI¼0.250-0.874; p¼0.015); analysing by mtDNA clusters, the cluster TJ
signiﬁcantly associated with lower risk of progression too (OR¼0.586;
CI¼0.366-0.939; p¼0.025). By comparing each of the mtDNA hap-
logroups with the most common haplogroup H in the regression
model, we detected that carriers of the mtDNA haplogroup T were at
lower risk for K&L grade progression (31.4% progressors) than carriers
of the most common mtDNA haplogroup H (50.6% progressors)
(OR¼0.414; CI¼0.204-0.844; p¼0.015); in terms of mtDNA clusters,
subjects in cluster TJ were at lower risk of progression than subjects in
the cluster HV (OR¼0.551; CI¼0.317-0.955; p¼0.034). Additionally,
either including mtDNA haplogroups or mtDNA clusters in the
regression model, both BMI (OR¼1.064; CI¼1.010-1.120; p¼0.020) and
bilateral KL¼1 at baseline (OR¼3.595; CI¼2.345-5.510; p<0.001) were
also signiﬁcantly associated with an increased risk of radiographic
progression of KOA attending to K&L grade. The AUC of this regression
model was 0.723 and 0.722 after including either haplogroups or
clusters respectively.
Conclusions: This work strengthens the hypothesis that mitochondrial
genome is a key factor in the progression of the KOA disease. As noted in
KOA patients of the OAI cohort, the early identiﬁcation and classiﬁcation
of patients with haplogroup T and the most common haplogroup H
would permit to identify those patients more prone to a rapid radio-
graphic progression of the disease.
